Update - PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg

In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 986P01.

news

This product defect correction relates to a previously identified issue, which has been determined to affect this one additional batch.

This is only a precautionary measure and there is no impact to the actual working of the medicine.

This correction does not affect any other lots or presentations of PALEXIA® or any other Seqirus products and only applies to product missing information on the blister foil.

Customers and pharmacists are requested to inspect the product prior to use or dispensing.

Customers should return any affected product to the point of purchase.

Seqirus apologises for any inconvenience caused – our customer service team can be contacted on 1800 008 275.